Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
DrugBank Accession Number
DB14445
Background

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.

There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)hemagglutinin3Q80689L6FNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Fluarix 2011/2012Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxosmithkline Biologicals S.A.2011-07-012011-07-01US flag
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2011-07-012012-06-30US flag
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2010-07-232011-06-30US flag
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularPhysicians Total Care, Inc.2010-09-162011-06-30US flag
FluzoneInfluenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2011-07-012012-06-30US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3Q2OMA2GNK
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Not AvailableCompletedNot AvailableAstrocytoma / Glioma / Oligodendroglioma1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableCentral Nervous System Neoplasm1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableFlu caused by Influenza / H1N1 / Human Immunodeficiency Virus Type 1 (HIV-1) Infection1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD)1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableSystemic Lupus Erythematosus1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Injection, suspensionIntramuscular
Injection, suspensionIntradermal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at July 05, 2018 18:03 / Updated at June 12, 2020 16:53